The association between oncogenic mutations with ICI resistance in MSI CRC was not confirmed for B2M, HLA, and JAK1/2, although these genes were found to be frequently mutated in MSI CRC [46,47]. This evidence concerns the gene JAK1 and colorectal carcinoma.